Francisco J. Esteva: Evolving nature of HER2 biomarkers
Francisco J. Esteva, Professor of Medicine at Zucker School of Medicine and Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared a post on LinkedIn:
“HER2 status plays a critical role in guiding breast cancer treatment but can evolve over time, presenting challenges in patient management.
At the 2024 San Antonio Breast Cancer Symposium, we presented preliminary findings on the evolving nature of HER2 biomarkers using Real World Data. This AI-powered analysis, conducted in collaboration with Clinithink and Healthix examined over 3 million clinical records from a diverse NYC population.
Our results reveal frequent changes in HER2 status—positive, low, and negative—within the same patients, highlighting the complexity of disease progression and its impact on treatment decisions. Additionally, the study underscores disparities in biomarker testing, with HER2 evaluated more often than markers like PIK3CA or AKT1.
These real-world insights from Northwell Cancer Institute and other institutions in the New York Metropolitan area emphasize the importance of continuous biomarker assessment and the potential of advanced AI technologies to inform personalized cancer care, improve treatment planning, and ultimately enhance outcomes for breast cancer patients.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023